Newsletter mensile Aiom
Anno V – Numero 62, Dicembre 2023
Comitato scientifico editoriale: Vanna Chiarion Sileni, Paola Queirolo
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini
Notizie dalla ricerca
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy

Background: Targeted therapy (TT) of BRAF V600 mutated unresectable melanoma with inhibitors of the MAPK pathway achieves response rates of up to 76%, but most patients develop secondary resistance. Albeit TT is strikingly efficacious during the first days of treatment, even in advanced cases, long-term survival is highly unlikely, especially in patients with unfavorable baseline characteristics like elevated lactate dehydrogenase (LDH). In patients … Continua a leggere

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

Background: BRAF+MEK inhibitors extend life expectancy of patients with BRAFV600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen. Methods: Patients with BRAFV600  Continua a leggere

Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib 

Background: Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib have demonstrated long-term clinical benefit in patients with melanoma, data on their efficacy in patients with BM are limited  Continua a leggere

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Background: Anti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete response (CR) and 30% with partial response (PR) within 12 months of treatment experience subsequent disease progression by 6 years. The nature and optimal management of this acquired resistance (AR) remains unknown … Continua a leggere

Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma

Background: The outcome of patients with resectable mucosal melanoma is poor. Toripalimab combined with axitinib has shown impressive results in metastatic mucosal melanoma with an objective response rate of 48.3% and a median progression-free survival of 7.5 months in a phase Ib trial. It was hypothesized that this combination administered in the neoadjuvant setting might induce a pathologic response in resectable mucosal melanoma, so we … Continua a leggere

Appuntamenti Aiom

Lo sviluppo dell’assistenza oncologica: nuovi bisogni e nuove risposte
Cuneo, 21 dicembre 2023

Making Palliative Care a part of your Oncology Practice
I mercoledì dell’oncologia
Webinar , 10 gennaio 2024 dalle 17.00 alle 18.15

Corso per Quality Assurance e Auditor
FAD , 11 gennaio – 18 marzo 2024

Back from San Antonio 2024
Genova, 12 – 13 gennaio 2024

Quali le sfide da affrontare nel Tumore Germinale del testicolo
I mercoledì dell’oncologia
Webinar , 17 gennaio 2024 dalle 17.00 alle 18.15

Best from San Antonio 2023
Webinar ECM, 25 gennaio 2024

La Ricerca alla Portata del Paziente 3.0
Roma, 26 gennaio 2024

Negrar (VR), 26 – 27 gennaio 2024

Questi e altri appuntamenti si possono consultare sul sito AIOM:


© 2023 Editore:
Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 388 8896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867

Per contattare la redazione e commentare le notizie clicca qui
Per consultare i numeri arretrati della newsletter clicca qui

Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati

“Si ringrazia Pierre Fabre Pharma s.r.l. per il supporto incondizionato”